CD47 and hematologic disorder: SRF231 is an anti-CD47 fully human IgG4 monoclonal antibody that binds CD47 on the surface of RBCs but does not cause phagocytosis [125]; it has been proposed in Phase 1 preclinical model of both advanced solid and hematologic malignancies.